{"disease":{"id":"metastatic-nasopharyngeal-nonkeratinizing-carcinoma","name":"metastatic nasopharyngeal nonkeratinizing carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04458909","title":"Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}